Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.43 USD
+0.08 (5.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $1.43 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENLV 1.43 +0.08(5.93%)
Will ENLV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for October 23rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy
Other News for ENLV
Enlivex Therapeutics (ENLV) Receives Continued Buy Rating with $13 Price Target | ENLV Stock News
Enlivex Therapeutics (ENLV) Completes Key Trial Stage for Allocetra
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data | ...
Enlivex reaffirms August 18 as target date for Phase II data announcement
Enlivex Therapeutics (ENLV) Receives Continued 'Buy' Rating from Analyst | ENLV Stock News